| P50 | author | Chaofan Li | Q96205055 |
| P2093 | author name string | Bin Wang | |
| | Changgui Li | |
| | Xian Zhou | |
| | Yiwei Zhong | |
| | Shuren Zhang | |
| | Aihua Dong | |
| | Zhonghuai He | |
| P2860 | cites work | Crystal structure of calcineurin-cyclophilin-cyclosporin shows common but distinct recognition of immunophilin-drug complexes | Q24535752 |
| | Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25(+)CD4(+) regulatory cells that control intestinal inflammation | Q24676080 |
| | Structure of RSV Fusion Glycoprotein Trimer Bound to a Prefusion-Specific Neutralizing Antibody | Q27677570 |
| | Cyclosporine A-sensitive, cyclophilin B-dependent endoplasmic reticulum-associated degradation | Q28475618 |
| | FOXP3+ regulatory T cells in the human immune system | Q29307487 |
| | Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis | Q29619821 |
| | Vbeta14(+) T cells mediate the vaccine-enhanced disease induced by immunization with respiratory syncytial virus (RSV) G glycoprotein but not with formalin-inactivated RSV | Q30448968 |
| | Interleukin-10 prevents spontaneous death of germinal center B cells by induction of the bcl-2 protein | Q33493389 |
| | CD46-induced human Treg enhance B-cell responses | Q33796410 |
| | Differential histopathology and chemokine gene expression in lung tissues following respiratory syncytial virus (RSV) challenge of formalin-inactivated RSV- or BBG2Na-immunized mice. | Q33870528 |
| | Respiratory syncytial virus interferon antagonist NS1 protein suppresses and skews the human T lymphocyte response | Q33886159 |
| | Plasmid DNA encoding the respiratory syncytial virus G protein is a promising vaccine candidate | Q33895116 |
| | Two distinct signal transmission pathways in T lymphocytes are inhibited by complexes formed between an immunophilin and either FK506 or rapamycin | Q33911404 |
| | Immune responses and disease enhancement during respiratory syncytial virus infection | Q33937152 |
| | CD25+ natural regulatory T cells are critical in limiting innate and adaptive immunity and resolving disease following respiratory syncytial virus infection | Q34055489 |
| | Role of T lymphocyte subsets in the pathogenesis of primary infection and rechallenge with respiratory syncytial virus in mice | Q34199969 |
| | Interleukin-10 in the regulation of T cell-induced colitis | Q34203664 |
| | Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine | Q34206177 |
| | The respiratory syncytial virus G protein conserved domain induces a persistent and protective antibody response in rodents | Q34222406 |
| | Prophylaxis with a respiratory syncytial virus (RSV) anti-G protein monoclonal antibody shifts the adaptive immune response to RSV rA2-line19F infection from Th2 to Th1 in BALB/c mice | Q34262180 |
| | Defective immunoregulation in RSV vaccine-augmented viral lung disease restored by selective chemoattraction of regulatory T cells | Q34326260 |
| | Type V collagen-induced oral tolerance plus low-dose cyclosporine prevents rejection of MHC class I and II incompatible lung allografts. | Q34385220 |
| | Treg cell resistance to apoptosis in DNA vaccination for experimental autoimmune encephalomyelitis treatment | Q34482931 |
| | Respiratory syncytial virus G protein and G protein CX3C motif adversely affect CX3CR1+ T cell responses | Q34486238 |
| | Interleukin-2 is essential for CD4+CD25+ regulatory T cell function | Q34550108 |
| | Nanoparticle vaccines encompassing the respiratory syncytial virus (RSV) G protein CX3C chemokine motif induce robust immunity protecting from challenge and disease | Q34990420 |
| | The G glycoprotein of respiratory syncytial virus depresses respiratory rates through the CX3C motif and substance P. | Q34996665 |
| | Absence of vaccine-enhanced RSV disease and changes in pulmonary dendritic cells with adenovirus-based RSV vaccine | Q35196230 |
| | Progress in understanding and controlling respiratory syncytial virus: still crazy after all these years | Q35566601 |
| | Neutralizing antibodies against the preactive form of respiratory syncytial virus fusion protein offer unique possibilities for clinical intervention | Q35778982 |
| | Activated CD4+CD25+ T cells selectively kill B lymphocytes | Q35848308 |
| | Immunogenicity and efficacy of recombinant RSV-F vaccine in a mouse model | Q36003444 |
| | Antibodies to the central conserved region of respiratory syncytial virus (RSV) G protein block RSV G protein CX3C-CX3CR1 binding and cross-neutralize RSV A and B strains | Q36005114 |
| | Regulatory T cells use programmed death 1 ligands to directly suppress autoreactive B cells in vivo | Q36068905 |
| | Altering the distribution of Foxp3(+) regulatory T cells results in tissue-specific inflammatory disease | Q36229433 |
| | CX3C chemokine mimicry by respiratory syncytial virus G glycoprotein | Q43690717 |
| | Effect of rapamycin on the cyclosporin A-resistant CD28-mediated costimulatory pathway | Q44010408 |
| | Tacrolimus and cyclosporine differ in their capacity to overcome ongoing allograft rejection as a result of their differential abilities to inhibit interleukin-10 production | Q44042070 |
| | Contrasting impacts of immunosuppressive agents (rapamycin, FK506, cyclosporin A, and dexamethasone) on bidirectional dendritic cell-T cell interaction during antigen presentation | Q44147193 |
| | Treatment of aplastic anemia with antilymphocyte globulin and methylprednisolone with or without cyclosporine. The German Aplastic Anemia Study Group | Q44262944 |
| | Respiratory syncytial virus morbidity, premorbid factors, seasonality, and implications for prophylaxis | Q44312792 |
| | Therapeutic monoclonal antibody treatment targeting respiratory syncytial virus (RSV) G protein mediates viral clearance and reduces the pathogenesis of RSV infection in BALB/c mice | Q45383435 |
| | Respiratory syncytial virus and neutrophil activation | Q45454401 |
| | Anti-G protein antibody responses to respiratory syncytial virus infection or vaccination are associated with inhibition of G protein CX3C-CX3CR1 binding and leukocyte chemotaxis | Q45553949 |
| | The small hydrophobic (SH) protein accumulates within lipid-raft structures of the Golgi complex during respiratory syncytial virus infection | Q45648966 |
| | Interleukin-12 Treatment during Immunization Elicits a T Helper Cell Type 1-like Immune Response in Mice Challenged with Respiratory Syncytial Virus and Improves Vaccine Immunogenicity | Q45787389 |
| | Effects of immunosuppressive drugs on purified human B cells: evidence supporting the use of MMF and rapamycin | Q46250074 |
| | Low-dose cyclosporine A therapy increases the regulatory T cell population in patients with atopic dermatitis. | Q47828390 |
| | Effects of Cyclosporine Immunosuppression in Insulin-Dependent Diabetes Mellitus of Recent Onset | Q49173574 |
| | Induction of adaptive T regulatory cells that suppress the allergic response by coimmunization of DNA and protein vaccines. | Q52690110 |
| | B cell resistance to Fas-mediated apoptosis contributes to their ineffective control by regulatory T cells in rheumatoid arthritis. | Q53082574 |
| | Naturally occurring lung CD4(+)CD25(+) T cell regulation of airway allergic responses depends on IL-10 induction of TGF-beta. | Q53576197 |
| | Peripheral CD4+ CD25+ Treg cell expansion in lung transplant recipients is not affected by calcineurin inhibitors | Q58910606 |
| | Cytotoxic T cells clear virus but augment lung pathology in mice infected with respiratory syncytial virus | Q36355326 |
| | Role of interleukin 10 in the B lymphocyte hyperactivity and autoantibody production of human systemic lupus erythematosus | Q36364479 |
| | A role for immune complexes in enhanced respiratory syncytial virus disease | Q36371267 |
| | Different protein tyrosine kinases are required for B cell antigen receptor-mediated activation of extracellular signal-regulated kinase, c-Jun NH2-terminal kinase 1, and p38 mitogen-activated protein kinase. | Q36401603 |
| | Immunopathology of RSV infection: prospects for developing vaccines without this complication | Q36605119 |
| | Cutting edge: Immunosuppressant as adjuvant for tolerogenic immunization | Q36649589 |
| | Long-term cultured CD40-activated B lymphocytes differentiate into plasma cells in response to IL-10 but not IL-4. | Q36672108 |
| | Early infection with respiratory syncytial virus impairs regulatory T cell function and increases susceptibility to allergic asthma | Q36810987 |
| | Nonstructural proteins 1 and 2 of respiratory syncytial virus suppress maturation of human dendritic cells | Q36845814 |
| | Understanding respiratory syncytial virus (RSV) vaccine-enhanced disease. | Q36961083 |
| | Dexamethasone promotes tolerance in vivo by enriching CD11clo CD40lo tolerogenic macrophages | Q36968804 |
| | Role of regulatory T cells during virus infection | Q37107677 |
| | The respiratory syncytial virus fusion protein and neutrophils mediate the airway mucin response to pathogenic respiratory syncytial virus infection | Q37123113 |
| | Regulatory T cells promote early influx of CD8+ T cells in the lungs of respiratory syncytial virus-infected mice and diminish immunodominance disparities | Q37127882 |
| | Risk factors in children hospitalized with RSV bronchiolitis versus non-RSV bronchiolitis | Q37144043 |
| | Regulatory T cells prevent Th2 immune responses and pulmonary eosinophilia during respiratory syncytial virus infection in mice | Q37252618 |
| | Breast cancer lung metastasis requires expression of chemokine receptor CCR4 and regulatory T cells. | Q37346143 |
| | Cell cycle arrest by transforming growth factor beta1 enhances replication of respiratory syncytial virus in lung epithelial cells | Q37451996 |
| | Immunosuppressive drugs and Tregs: a critical evaluation! | Q37583262 |
| | Eosinophils and Th2 immunity: contemporary insights | Q37672261 |
| | Prospects for defined epitope vaccines for respiratory syncytial virus | Q37721415 |
| | Fatality rates in published reports of RSV hospitalizations among high-risk and otherwise healthy children | Q37776266 |
| | Homeostatic control of regulatory T cell diversity. | Q38183674 |
| | Cyclophilin inhibition as potential therapy for liver diseases | Q38232505 |
| | Respiratory Syncytial Virus: pathology, therapeutic drugs and prophylaxis. | Q38255545 |
| | Nonstructural proteins of respiratory syncytial virus suppress premature apoptosis by an NF-kappaB-dependent, interferon-independent mechanism and facilitate virus growth | Q40199774 |
| | Cyclophilin A-deficient mice are resistant to immunosuppression by cyclosporine | Q40425586 |
| | Two distinct action mechanisms of immunophilin-ligand complexes for the blockade of T-cell activation | Q40606038 |
| | An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine | Q40940832 |
| | The mechanism of action of cyclosporin A and FK506. | Q41114675 |
| | Factors associated with early remission of type I diabetes in children treated with cyclosporine | Q41282880 |
| | Respiratory syncytial virus G protein CX3C motif impairs human airway epithelial and immune cell responses | Q41838015 |
| | Cutting edge: mechanisms of IL-2-dependent maintenance of functional regulatory T cells | Q41872700 |
| | Motavizumab treatment of infants hospitalized with respiratory syncytial virus infection does not decrease viral load or severity of illness. | Q42248000 |
| | Systemic eosinophil response induced by respiratory syncytial virus | Q42496152 |
| | Synergistic Bcl-2 inhibition by ABT-737 and cyclosporine A. | Q42517322 |
| | Influence of combined treatment of low dose rapamycin and cyclosporin A on corneal allograft survival | Q43007021 |
| | Rapamycin, unlike cyclosporine A, enhances suppressive functions of in vitro-induced CD4+CD25+ Tregs | Q43244822 |
| | B lymphocyte inhibition of anti-tumor response depends on expansion of Treg but is independent of B-cell IL-10 secretion | Q43418649 |
| | Efficient lung recruitment of respiratory syncytial virus-specific Th1 cells induced by recombinant bacillus Calmette-Guérin promotes virus clearance and protects from infection | Q43610628 |
| | Sanglifehrin A, a novel cyclophilin-binding compound showing immunosuppressive activity with a new mechanism of action | Q43628930 |
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | cyclosporine | Q367700 |
| P304 | page(s) | 1721-1731 | |
| P577 | publication date | 2016-01-20 | |
| P1433 | published in | Journal of Immunology | Q3521441 |
| P1476 | title | A Recombinant G Protein Plus Cyclosporine A-Based Respiratory Syncytial Virus Vaccine Elicits Humoral and Regulatory T Cell Responses against Infection without Vaccine-Enhanced Disease | |
| P478 | volume | 196 | |